Actively Recruiting
Evaluating the Safety and Preliminary Effectiveness of Oral JAB-8263 for Active Rheumatoid Arthritis in a Phase IIa Study
Led by Jacobio Pharmaceuticals Co., Ltd. · Updated on 2026-09-28
32
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating JAB-8263 for patients with active rheumatoid arthritis in an open-label, multi-center Phase IIa study. This study has two phases, starting with a safety exploration phase where participants with active RA receive JAB-8263 alone for 4 weeks. The goal is to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary effectiveness of JAB-8263 in this population. Participants receive variable oral doses of JAB-8263 every two days over a 28-day treatment period. This single-group study focuses on treatment with JAB-8263 without a placebo or comparator group. The treatment phase lasts up to approximately 12 weeks, during which participants are monitored closely for safety and response. During the study, participants undergo regular evaluations to monitor safety and treatment effects, including assessments like the American College of Rheumatology 20, 50, and 70 response rates, as well as disease activity indices like CDAI and SDAI. Researchers will track overall safety and tolerability up to about 12 weeks. The total participation duration extends until study completion at the end of 2027, including follow-up as needed.
CONDITIONS
Brief Title
A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
Research Team
J
Jun Yang Jun Project Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here